Date: Thursday, October 30th, 2025
Time: 2:00pm – 3:00pm ET

WEBINAR TOPIC:

Alhemo (concizumab-mtci): A new option for patients living with hemophilia.

OBJECTIVE:

To provide an update on prescribing information of the recently FDA-approved indication in patients with hemophilia A or B without inhibitors, and supporting data from the explorer8 trial.

AUDIENCE:

All HTC Staff.

SPEAKER:

Ryan Rodriguez, PharmD, MS, BCPS, is a Medical Liaison for rare blood disorders at Novo Nordisk covering the Midwest. His responsibilities include learning from and sharing medical information with clinicians who treat patients with hemophilia and other bleeding disorders, aligning with his passion for evidence-based patient care.

Prior to joining Novo Nordisk, Ryan earned his PharmD degree from the University of Florida, and then served as Clinical Associate Professor at the University of Illinois Chicago College of Pharmacy, where he also earned his Master’s degree in epidemiology. Throughout his career, Ryan has been involved in medical communications, evidence generation and publication, and formulary management for various public and private entities.